Enhancing effect of bevacizumab in the classic bleomycin, etoposide, cisplatin treatment applied in human testicular germ cell tumors
Öz
Purpose: This study aimed to evaluate the therapeutic potential of Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, in combination with the standard Bleomycin, Etoposide, and Cisplatin (BEP) regimen for the treatment of testicular germ cell tumors (TGCTs). The primary focus was to investigate its ability to enhance treatment efficacy while reducing cytotoxic side effects.
Materials and Methods: The half-maximal inhibitory concentration (IC₅₀) of the BEP regimen was determined in the 1618-K human TGCT cell line and subsequently combined with varying concentrations of Bevacizumab. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Expression levels of VEGF, Bax, Bcl-2, and Caspase-3 were analyzed by immunohistochemistry.
Results: Bevacizumab significantly reduced cell viability in a dose-dependent manner. Bax expression in Group 2 (2.05 ± 1.04) was significantly lower than in the control group (8.63 ± 2.57;). Caspase-3 expression in Group 2 (0.49 ± 0.08) was markedly decreased compared with the control (5.10 ± 3.82), and a similar reduction was also observed in Group 3. Despite the absence of substantial changes in apoptotic markers, the reduction in cell viability suggests that Bevacizumab may act through alternative mechanisms.
Conclusion: By targeting tumor vascularity, Bevacizumab may enhance the therapeutic efficacy of the BEP regimen in TGCT treatment. These findings support the potential role of Bevacizumab as an adjunctive agent in TGCT therapy and highlight the need for further validation through in vivo studies.
Anahtar Kelimeler
testicular germ cell tumors, bevacizumab, VEGF, cell culture techniques
Destekleyen Kurum
This study was supported by the Afyon Health Sciences University Scientific Research Projects (BAP) with the project number 17-SAĞ.BİL-03.
Proje Numarası
2017/2/45
Etik Beyan
This study was approved by the Afyon Kocatepe University Human Ethics Committee (AKÜİEK) with the approval number 2017/2/45 on February 3, 2017.
Kaynakça
- Das MK, Evensen HSF, Furu K, Haugen TB. miRNA-302s may act as oncogenes in human testicular germ cell tumours. Sci Rep. 2019;9:14377.
- Maruyama Y, Sadahira T, Mitsui Y, Araki M, Wada K, Tanimoto R et al. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors. Med Oncol. 2018;35:80.
- Kayıkçı M, Çam H. Tedavi evresi I nonseminomatöz testis tümörlerinde tedavi yaklaşımları. Düzce Tıp Fak Derg. 2005;3:40–4.
- Kwan E, Beck S, Amir E, Jewett M, Sturgeon J, Cartwright L et al. Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumors. Clin Genitourin Cancer. 2017;16:E193–9.
- Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M. Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury. J Pharmacol Sci. 2006;100:65–72.
- Mori R, Fujimoto D, Ito M, Tomii K. Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature. Oncotarget. 2017;8:50296–50305.
- Imai A, Ichigo S, Matsunami K, Takagi H, Kawabata I. Ovarian function following targeted anti-angiogenic therapy with bevacizumab. Mol Clin Oncol. 2017;6:807–10.
- Zheng Y, Zhou R, Cai J, Yang N, Wen Z, Zhang Z et al. Matrix stiffness triggers lipid metabolic cross-talk between tumor and stromal cells to mediate bevacizumab resistance in colorectal cancer liver metastases. Cancer Res. 2023;83:3411–24.
- Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2023;11:e008409.
- Liu M, Hales BF, Robaire B. Effects of four chemotherapeutic agents, bleomycin, etoposide, cisplatin, and cyclophosphamide, on DNA damage and telomeres in a mouse spermatogonial cell line. Biol Reprod. 2014;90:72.
